Merck (NYSE: MRK) reported its third quarter 2024 earnings results today.
Sales grew 4% year-over-year to $16.7 billion. Excluding FX, sales growth was 7%.
GAAP net income decreased 33% to $3.15 billion, or $1.24 per share, compared to last year. Adjusted EPS fell 26% to $1.57.
For the full year of 2024, the company expects sales of $63.6-64.1 billion and adjusted EPS of $7.72-7.77.
The post Infographic: How Merck (MRK) performed in Q3 2024 first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
